Studies show BPC-157 improved outcomes in inflammatory bowel disease models that share inflammatory mechanisms with rheumatoid arthritis
Injectable GHK-Cu is not FDA-approved for human use
Typically, orders take 3 weeks
References [1] National Library of Medicine, Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts, Chang, C., Tsai, W, Hsu, Y, Pang, J.S., 2014 [2] National Library of Medicine, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, Vasireddi, N., Hahamyan, H., Salata, M., Karns, M., Calcei, J., Voos, J., Apostolakos, J., July 2025 [3] National Library of Medicine, Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts, Chang, C., Tsai, W., Hsu, Y., Pang, JS., November 2014